載入...
A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children
Preterm infants ≤ 35 weeks' gestational age (GA), and children ≤ 24 months of age with bronchopulmonary dysplasia (BPD) or hemodynamically significant congenital heart disease (hsCHD) are at high risk for developing severe respiratory syncytial virus (RSV) disease. In 3 previous randomized, pla...
Na minha lista:
| 發表在: | Hum Vaccin Immunother |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Taylor & Francis
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5443059/ https://ncbi.nlm.nih.gov/pubmed/25483483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.32082 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|